Stock-Based Compensation

6 Months Ended

Jun. 30, 2021

Share-based Payment Arrangement [Abstract]

We recognized total stock-based compensation expense in our Condensed Consolidated Statements of Operations as follows (in thousands):


	Three months ended June 30,				Six months ended June 30,
	2021		2020		2021		2020
Cost of goods sold	$	716	$	664	$	1,443	$	1,424
Research and development	13,479		14,161		27,641		29,614
General and administrative	9,519		8,546		18,528		16,544
Impairment of assets and other costs for terminated program	—		—		—		1,025
Total stock-based compensation	$	23,714	$	23,371	$	47,612	$	48,607

The stock-based compensation expense reported in impairment of assets and other costs for terminated program resulted from executive severance. We accounted for this as a liability award as of March 31, 2020, which we reclassified into equity in three months ended June 30, 2020.

We issued stock-based awards and resulting shares of our common stock as follows (shares in thousands):


	Three months ended June 30,				Six months ended June 30,
	2021		2020		2021		2020
Options granted	157		—		278		49
Weighted-average grant-date fair value of options granted	$	9.78	$	—	$	10.23	$	11.88
RSUs granted	520		275		887		520
Weighted-average grant-date fair value of RSUs granted	$	18.20	$	21.65	$	19.21	$	20.36
Shares issued under equity compensation plans	1,483		947		3,682		2,305

On June 10, 2021, the stockholders of Nektar approved an amendment to the Amended and Restated 2017 Performance Incentive Plan to increase the aggregate number of shares of Common Stock authorized for issuance thereunder by 5,000,000 shares.